Marksans Pharma has made a significant move to strengthen its presence in Europe by acquiring QliniQ B.V., a Dutch pharmaceutical firm, for EUR 7.5 million.
This acquisition marks Marksans' entry into the Dutch healthcare market, enhancing its distribution and market access capabilities across regulated European regions. The deal is seen as a crucial step in facilitating the commercialization of both existing and future products within the European Union.
Mark Saldanha, the Chairman and Managing Director of Marksans Pharma, highlighted that this acquisition will provide direct access to the Netherlands market, thereby bolstering the company's footprint in Europe.
QliniQ B.V. specializes in the distribution of prescription medications and medical devices, maintaining strong connections with various healthcare stakeholders in the Netherlands. The partnership is expected to leverage Marksans' robust product development and manufacturing strengths, setting the stage for future growth in the European market.
This strategic acquisition underscores the increasing importance of market access in the competitive landscape of European pharmaceuticals, reflecting a broader trend of consolidation aimed at enhancing operational capabilities and market reach.